AgomAb Therapeutics NV (AGMB) Common Equity (2023 - 2026)
Agomab Therapeutics (AGMB) reported Common Equity of $308.46 million for Q2 2026.
Powered by 
Analysis
AgomAb Therapeutics NV (AGMB) Common Equity (2023 - 2026) Analysis & Trends
At the end of FY2025, Agomab Therapeutics posted Common Equity of $147.89 million, down 27.3% from FY2024.
- By year, Common Equity came in at $203.57 million in FY2024 (+24.3%) and $163.81 million in FY2023.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 303.11 Mn |
| Dec 31, 2025 | 153.77 Mn |
| Dec 31, 2024 | 195.72 Mn |
| Dec 31, 2023 | 167.61 Mn |
API Access
AgomAb Therapeutics NV Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=AGMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "AGMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=AGMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();